Format

Send to

Choose Destination
See comment in PubMed Commons below
Cancer Cell. 2015 Sep 14;28(3):281-3. doi: 10.1016/j.ccell.2015.08.009.

Engineering Anti-myeloma Responses Using Affinity-Enhanced TCR-Engineered T Cells.

Author information

1
Clinica Universidad de Navarra, Centro de Investigacion Medica Aplicada (CIMA), IDISNA, 31008 Pamplona, Spain. Electronic address: sanmiguel@unav.es.
2
Clinica Universidad de Navarra, Centro de Investigacion Medica Aplicada (CIMA), IDISNA, 31008 Pamplona, Spain.

Abstract

NY-ESO-1 TCR-engineered T cells have shown activity in solid tumors. Recent work supports their use in multiple myeloma by showing that ex vivo antigen-specific expanded T cells traffic to and persist in bone marrow, are well tolerated, and produce promising response rates when infused after stem cell transplantation.

PMID:
26373276
DOI:
10.1016/j.ccell.2015.08.009
[Indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center